Page 152 - 南京医科大学自然版

第45卷第1期
·146 · 南 京 医 科 大 学 学 报 2025年1月

［21］CHERRY E M，ABBOTT D，AMAYA M，et al. Venetoclax ［33］CORTES J E，TALLMAN M S，SCHILLER G J，et al.
and azacitidine compared with induction chemotherapy Phase 2b study of 2 dosing regimens of quizartinib mono⁃
for newly diagnosed patients with acute myeloid leuke⁃ therapy in FLT3 ⁃ ITD ⁃ mutated，relapsed or refractory
mia［J］. Blood Adv，2021，5（24）：5565-5573 AML［J］. Blood，2018，132（6）：598-607
［22］TARLOCK K，LAMBLE A J，WANG Y C，et al. CEBPA⁃ ［34］CORTES J E，KHALED S，MARTINELLI G，et al. Quizar⁃
bZip mutations are associated with favorable prognosis in tinib versus salvage chemotherapy in relapsed or refractory
de novo AML：a report from the Children’s Oncology FLT3 ⁃ ITD acute myeloid leukaemia（QuANTUM ⁃ R）：a
Group［J］. Blood，2021，138（13）：1137-1147 multicentre，randomised，controlled，open⁃label，phase 3
［23］ TAUBE F，GEORGI J A，KRAMER M，et al. CEBPA trial［J］. Lancet Oncol，2019，20（7）：984-997
mutations in 4708 patients with acute myeloid leukemia： ［35］CORTES J，PERL A E，DÖHNER H，et al. Quizartinib，
differential impact of bZIP and TAD mutations on out⁃ an FLT3 inhibitor，as monotherapy in patients with relapsed
come［J］. Blood，2022，139（1）：87-103 or refractory acute myeloid leukaemia：an open ⁃ label，
［24］WAKITA S，SAKAGUCHI M，OH I，et al. Prognostic im⁃ multicentre，single⁃arm，phase 2 trial［J］. Lancet Oncol，
pact of CEBPA bZIP domain mutation in acute myeloid 2018，19（7）：889-903
leukemia［J］. Blood Adv，2022，6（1）：238-247 ［36］WANG E S，GOLDBERG A D，WALTER R B，et al. Long⁃
［25］AWADA H，DURMAZ A，GURNARI C，et al.Machine term results of a phase 2 trial of crenolanib combined with
learning integrates genomic signatures for subclassifica⁃ 7+3 chemotherapy in adults with newly diagnosed FLT3
tion beyond primary and secondary acute myeloid leuke⁃ mutant AML［J］. J Clinic Oncol，2022，40（16）：7007
mia［J］. Blood，2021，138（19）：1885-1895 ［37］SALLMAN D A，DEZERN A E，GARCIA⁃MANERO G，
［26］BERNARD E，TUECHLER H，GREENBERG P L，et al. et al. Eprenetapopt（APR⁃246）and azacitidine in TP53⁃
Molecular international prognostic scoring system for my⁃ mutant myelodysplastic syndromes［J］. J Clin Oncol，
elodys ⁃ plastic syndromes［J］. NEJM Evidence，2022，1 2021，39（14）：1584-1594
（7）：2200008 ［38］CLUZEAU T，SEBERT M，RAHMÉ R，et al. Epreneta⁃
［27］CARAVELLA J A，LIN J，DIEBOLD R B，et al. Structure⁃ popt plus azacitidine in TP53 ⁃ mutated myelodysplastic
based design and identification of FT ⁃ 2102（Olutas⁃ syndromes and acute myeloid leukemia：a phase Ⅱ study
idenib），a potent mutant⁃selective IDH1 inhibitor［J］. J by the groupe francophone des myélodysplasies（GFM）［J］.
Med Chem，2020，63（4）：1612-1623 J Clin Oncol，2021，39（14）：1575-1583
［28］CORTES J E，FENAUX P，YEE K，et al. Oluta⁃sidenib ［39］MISHRA A，TAMARI R，DEZERN A E，et al. Epreneta⁃
（FT⁃2102）induces durable complete remissions in patients popt plus azacitidine after allogeneic hematopoietic stem⁃
with relapsed/refractory mIDH1 acute myeloid leukemia. cell transplantation for TP53⁃mutant acute myeloid leuke⁃
Results from a planned interim analysis of a phase 2 piv⁃ mia and myelodysplastic syndromes［J］. J Clin Oncol，
otal clinical trial［J］.Blood，2022，140（1）：6193-6196 2022，40（34）：3985-3993
［29］LACHOWIEZ C A，GARCIA J S，BORTHAKUR G，et al. ［40］ISSA G C，ALDOSS I，DIPERSIO J F，et al. The menin in⁃
A phase Ⅰb/Ⅱ study of ivosidenib with venetoclax +/- hibitor SNDX⁃5613（revumenib）leads to durable respons⁃
azacitidine in IDH1⁃mutated hematologic malignancies［J］. es in patients（Pts）with KMT2A⁃rearranged or NPM1 mu⁃
J Clinic Oncol，2022，40（16）：7018 tant AML：updated results of a phase（Ph）1 study［J］.
［30］DÖHNER H，WEBER D，KRZYKALLA J，et al. Midostau⁃ Blood，2022，140（1）：150-152
rin plus intensive chemotherapy for younger and older pa⁃ ［41］ERBA H P，FATHI A T，ISSA G C，et al. Update on a
tients with AML and FLT3 internal tandem duplications［J］. phase 1/2 first ⁃ in ⁃ human study of the menin ⁃ KMT2A
Blood Adv，2022，6（18）：5345-5355 （MLL）inhibitor ziftomenib（KO⁃539）in patients with re⁃
［31］DÖHNER K，THIEDE C，JAHN N，et al. Impact of NPM1/ lapsed or refractory acute myeloid leukemia［J］. Blood，
FLT3⁃ITD genotypes defined by the 2017 European Leu⁃ 2022，140（1）：153-156
kemiaNet in patients with acute myeloid leukemia［J］. ［42］ISSA G C，CUGLIEVAN B，STEIN E，et al. Outcomes af⁃
Blood，2020，135（5）：371-380 ter transplant in relapsed/refractory KMT2Ar（MLLr）and
［32］MAZIARZ R T，LEVIS M，PATNAIK M M，et al. Mi⁃ mNPM1（NPM1c）leukemia patients achieving remissions
dostaurin after allogeneic stem cell transplant in patients after menin inhibition：SNDX⁃5613（revumenib）Ph1 expe⁃
with FLT3⁃internal tandem duplication⁃positive acute my⁃ rience［J］. Blood，2022，140（1）：914-916
eloid leukemia［J］. Bone Marrow Transplant，2021，56 ［收稿日期］ 2024-07-13
（5）：1180-1189 （本文编辑：唐 震）